Svenska Cellulosa AB (SCA) has entered into an agreement to acquire Luxembourg, Germany-based BSN Medical Ltd. for about $2.9 billion. The Stockholm, Sweden-based company is acquiring BSN from private equity firm EQT, and the transaction is expected to close during 2Q17. The acquisition will give SCA access to the wound care market and will be fully debt funded. The BSN Medical buy comes on the heels of SCA revealing it would split into two distinct companies – a global hygiene firm and forest products company. SCA said that a distribution and listing of its hygiene...
Svenska Cellulosa AB (SCA) has entered into an agreement to acquire Luxembourg, Germany-based BSN Medical Ltd. for about $2.9 billion. The Stockholm, Sweden-based company is acquiring BSN from private equity firm EQT, and the transaction is expected to close during 2Q17. The acquisition will give SCA access to the wound care market and will be fully debt funded.
Women's health care startup Femasys Inc. has raised $40 million in a series C round. The Suwanee, Ga.-based company will use the funding to support the further development of Fembloc, a non-surgical, permanent contraception solution. The transaction was arranged by Salem Partners, a Los Angeles-based investment bank, which also participated as a principal investor. The funding comes at the same time the private company revealed it received FDA approval to launch a prospective, multicenter, trial to evaluate the safety of the Fembloc while preventing pregnancy. Femasys said the study will enroll women who desire permanent...
Women's health care startup Femasys Inc. has raised $40 million in a series C round. The Suwanee, Ga.-based company will use the funding to support the further development of Fembloc, a non-surgical, permanent contraception solution. The transaction was arranged by Salem Partners, a Los Angeles-based investment bank, which also participated as a principal investor.
Novocure Ltd. is hoping to apply its Tumor Treating Fields (TTFields) therapy to both ovarian cancer and pancreatic cancer. During the St. Helier, Jersey Isle-based firm's research and development day, it revealed top line results from two studies that showed the effectiveness of TTFields to treat these cancer patient populations. TTFields are low-intensity alternating electric fields used to halt tumor growth. Novocure said the shape and special characteristics of rapidly dividing tumor cells make them susceptible to damage when exposed to TTFields. The company said the delivery of these fields is through a portable home...
Novocure Ltd. is hoping to apply its Tumor Treating Fields (TTFields) therapy to both ovarian cancer and pancreatic cancer. During the St. Helier, Jersey Isle-based firm's research and development day, it revealed top line results from two studies that showed the effectiveness of TTFields to treat these cancer patient populations.
Insulet Corp. said Horizon, its artificial pancreas, could be on the U.S. market in late 2019. Horizon is the Billerica, Mass.-based firm's first foray into continuous glucose monitoring-automated insulin delivery. If Insulet's Horizon gains FDA approval, it would go up against Dublin-based, Medtronic plc's Minimed 670G artificial pancreas, which received FDA approval in September and is set to launch in April of next year. (See Medical Device Daily, Sept. 29, 2016.) Even though Horizon will be two years behind the Minimed 670G's launch, analysts said this could be to the Insulet's benefit. "While Insulet is...
Insulet Corp. said Horizon, its artificial pancreas, could be on the U.S. market in late 2019. Horizon is the Billerica, Mass.-based firm's first foray into continuous glucose monitoring-automated insulin delivery. If Insulet's Horizon gains FDA approval, it would go up against Dublin-based, Medtronic plc's Minimed 670G artificial pancreas, which received FDA approval in September and is set to launch in April of next year. (See Medical Device Daily, Sept. 29, 2016.)
Edwards Lifesciences Corp. said its 4Q16 revenue will come in at the low end of its $750 million to $790 million guidance range, but strong developments in the company's product pipeline will give it a solid foundation long term. During its annual analyst day, the Irvine, Calif.-based company emphasized that the transcatheter aortic valve replacement (TAVR) market would be at the heart of its plans for the coming year. Analysts seemed to walk away from the event with a highly favorable perspective of the company's general direction. "While the initial reaction to the 4Q16 guidance...
